Bin Yao

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio et al. · Journal of Clinical Oncology · 2015 · 2.5K citations · Full text

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Arlene Chan, Suzette Delaloge, Frankie A. Holmes et al. · The Lancet Oncology · 2016 · 551 citations

Breast Oncology, Health Sciences, Medicine +9

Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.

Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng et al. · Journal of Clinical Oncology · 2019 · 99 citations

Her2-directed Regimens, Breast Oncology, Oncology +12

Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer

Robert G. Prosnitz, Bin Yao, Catherine L. Farrell et al. · International Journal of Radiation Oncology*Biology*Physics · 2005 · 84 citations

Advanced Head, Radiation Medicine, Neck Cancer +11

Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs

Xin Chen, Ruojun Wang, Xinshu Zhao et al. · Carcinogenesis · 2006 · 80 citations · Full text

Mesenchymal Stem Cells, Tumor Biology, Oncogenic Agent +14